Biospyder Technologies, Inc.

Biospyder Technologies, Inc., doing business as Biospyder, is a small business manufacturer headquartered in Carlsbad, California that specializes in advanced genomic analysis services and products. The company is registered in SAM.gov and holds federal contract prime awardee status with multiple agencies. Biospyder's core competency centers on targeted RNA sequencing and gene expression profiling through its proprietary Tempo-Seq platform and emerging Tempo-LINC single-cell technology, which enable high-throughput transcriptomic analysis of biological samples. These platforms support federal agencies in understanding environmental impacts on gene expression and public health, making Biospyder a critical partner in computational toxicology, exposure research, and biomedical investigations.

Through its federal prime contract awards, Biospyder has provided extensive targeted RNA sequencing and gene expression profiling services, primarily to the Environmental Protection Agency's Office of Research and Development under multiple delivery orders issued against its $25 million indefinite delivery/indefinite quantity (IDIQ) contract awarded in September 2025 and its previously held $9.5 million IDIQ contract. The company has delivered Tempo-Seq analysis services on thousands of samples, including cell lysates, tissue samples, whole body homogenates, and purified RNA from various cell types and organisms, with analysis depths ranging from 1 million to 30 million mapped reads per sample. Recent prime contract awards include a $520,914.24 delivery order for transcriptomics research and molecular analysis services, a $1,010,598.12 delivery order for targeted RNA-seq analysis of cell lysates generated at EPA's Center for Computational Toxicology and Exposure laboratory, and numerous other delivery orders valued between $10,000 and $1.3 million for similar services. The EPA Office of Research and Development has been Biospyder's primary federal customer, with contracts supporting high-throughput transcriptomics research for the National Center for Computational Toxicology and chemical safety initiatives. Additionally, the Department of Veterans Affairs Veterans Integrated Service Network 22 has awarded Biospyder contracts valued at approximately $150,800 for transcriptome sequencing services utilizing the Tempo-Seq platform on murine models. Biospyder also serves as a subcontractor to Battelle Memorial Institute, supplying Tempo-Seq assay services, kits, and reagents since 2021. These contracts were awarded without set-aside designations, reflecting the company's qualification as a capable prime contractor in the commercial genomic analysis marketplace.

Biospyder has received federal grant awards from the National Institute of General Medical Sciences to develop and validate its advanced single-cell gene expression profiling technologies. The company was awarded two Phase I and Phase II Small Business Innovation Research (SBIR) grants for the development of Tempo-LINC, a high-throughput, high-sensitivity single-cell gene expression profiling assay designed to overcome limitations in existing single-cell sequencing methodologies. The Phase I SBIR grant, awarded in April 2021 with an ultimate completion date of March 31, 2023, supported the initial development of Tempo-LINC as an instrument-free approach that can process 96 samples of 1,000 cells per run with simplified workflows amenable to automation. The Phase II SBIR grant, awarded in June 2023 with a completion date of May 31, 2025, continues development of Tempo-LINC to provide data measuring low, moderate, and highly expressed genes from single cells with quantitative measurements and dynamic expression ranges comparable to bulk cell samples. Additionally, Biospyder participates as a sub-grantee to the Jackson Laboratory, providing reagents, protocols, and sequencing services for a spatial transcriptomics research project initiated in March 2023 that adapts the Tempo-LINC platform to provide single-cell resolution in fixed tissue sections using deterministic barcoding by ligation in tissue (DBIT) technology.

Biospyder currently holds two active indefinite delivery/indefinite quantity (IDIQ) federal contract vehicles. The primary vehicle is a $25 million single-award IDIQ contract set aside for small businesses, awarded by the Environmental Protection Agency's Office of Research and Development in September 2025 with a period of performance through September 2030, which provides high-throughput transcriptomics services including targeted RNA sequencing analyses on various cell types and sample matrices with analysis depths ranging from 3 to 30 million mapped reads per sample. The second active IDIQ is the legacy $9.5 million small business set-aside contract with the EPA Office of Research and Development, awarded in September 2021 with an ultimate completion date of August 31, 2026, which similarly supports evaluation of treatment-related changes in gene expression in samples from animal or plant species of interest. Biospyder also maintains a $150,800 IDIQ contract with the Department of Veterans Affairs Veterans Integrated Service Network 22, awarded in June 2021 with a period of performance through September 2024 (extended through September 2025), for transcriptome sequencing services including Tempo-Seq kits, reagents, and sequencing runs on Illumina instruments. These IDVCs enable the EPA and VA to flexibly issue task orders and delivery orders for Biospyder's specialized genomic analysis services without the need for individual competitive solicitations, streamlining the procurement process for high-throughput transcriptomics research supporting federal environmental health, toxicology, and biomedical research missions.